TISIDB

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus, nucleolus Cytoplasm
Domain	PF00297 Ribosomal protein L3
Function	The L3 protein is a component of the large subunit of cytoplasmic ribosomes.

> Gene Ontology [ TOP ]
Biological Process	GO:0000027 ribosomal large subunit assembly GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay GO:0000956 nuclear-transcribed mRNA catabolic process GO:0006364 rRNA processing GO:0006401 RNA catabolic process GO:0006402 mRNA catabolic process GO:0006413 translational initiation GO:0006612 protein targeting to membrane GO:0006613 cotranslational protein targeting to membrane GO:0006614 SRP-dependent cotranslational protein targeting to membrane GO:0016072 rRNA metabolic process GO:0019058 viral life cycle GO:0019080 viral gene expression GO:0019083 viral transcription GO:0019439 aromatic compound catabolic process GO:0022613 ribonucleoprotein complex biogenesis GO:0022618 ribonucleoprotein complex assembly GO:0034470 ncRNA processing GO:0034655 nucleobase-containing compound catabolic process GO:0042254 ribosome biogenesis GO:0042255 ribosome assembly GO:0042273 ribosomal large subunit biogenesis GO:0044033 multi-organism metabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0045047 protein targeting to ER GO:0046700 heterocycle catabolic process GO:0070670 response to interleukin-4 GO:0070972 protein localization to endoplasmic reticulum GO:0071353 cellular response to interleukin-4 GO:0071826 ribonucleoprotein complex subunit organization GO:0072599 establishment of protein localization to endoplasmic reticulum GO:0072657 protein localization to membrane GO:0090150 establishment of protein localization to membrane GO:1901361 organic cyclic compound catabolic process
Molecular Function	GO:0003735 structural constituent of ribosome GO:0008097 5S rRNA binding GO:0019843 rRNA binding
Cellular Component	GO:0005840 ribosome GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0015934 large ribosomal subunit GO:0022625 cytosolic large ribosomal subunit GO:0022626 cytosolic ribosome GO:0030055 cell-substrate junction GO:0044391 ribosomal subunit GO:0044445 cytosolic part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03010 Ribosome
Reactome	R-HSA-157279: 3' -UTR-mediated translational regulation R-HSA-72737: Cap-dependent Translation Initiation R-HSA-1643685: Disease R-HSA-156842: Eukaryotic Translation Elongation R-HSA-72613: Eukaryotic Translation Initiation R-HSA-72764: Eukaryotic Translation Termination R-HSA-72689: Formation of a pool of free 40S subunits R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit R-HSA-74160: Gene Expression R-HSA-5663205: Infectious disease R-HSA-168254: Influenza Infection R-HSA-168255: Influenza Life Cycle R-HSA-168273: Influenza Viral RNA Transcription and Replication R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression R-HSA-6791226: Major pathway of rRNA processing in the nucleolus and cytosol R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-392499: Metabolism of proteins R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) R-HSA-975956: Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) R-HSA-927802: Nonsense-Mediated Decay (NMD) R-HSA-156902: Peptide chain elongation R-HSA-1799339: SRP-dependent cotranslational protein targeting to membrane R-HSA-2408522: Selenoamino acid metabolism R-HSA-2408557: Selenocysteine synthesis R-HSA-72766: Translation R-HSA-192823: Viral mRNA Translation R-HSA-72312: rRNA processing R-HSA-8868773: rRNA processing in the nucleus and cytosol

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03010 Ribosome

Reactome

R-HSA-157279: 3' -UTR-mediated translational regulation
R-HSA-72737: Cap-dependent Translation Initiation
R-HSA-1643685: Disease
R-HSA-156842: Eukaryotic Translation Elongation
R-HSA-72613: Eukaryotic Translation Initiation
R-HSA-72764: Eukaryotic Translation Termination
R-HSA-72689: Formation of a pool of free 40S subunits
R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit
R-HSA-74160: Gene Expression
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression
R-HSA-6791226: Major pathway of rRNA processing in the nucleolus and cytosol
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-392499: Metabolism of proteins
R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
R-HSA-975956: Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
R-HSA-927802: Nonsense-Mediated Decay (NMD)
R-HSA-156902: Peptide chain elongation
R-HSA-1799339: SRP-dependent cotranslational protein targeting to membrane
R-HSA-2408522: Selenoamino acid metabolism
R-HSA-2408557: Selenocysteine synthesis
R-HSA-72766: Translation
R-HSA-192823: Viral mRNA Translation
R-HSA-72312: rRNA processing
R-HSA-8868773: rRNA processing in the nucleus and cytosol

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RPL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RPL3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.65	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RPL3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.33	0.207
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.017	0.997
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.579	0.878
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.016	0.965
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.163	0.961
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.166	0.969
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.097	0.881
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.068	0.982
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.258	0.94
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.571	0.867
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.323	0.951
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.204	0.0142

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RPL3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RPL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RPL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RPL3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RPL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RPL3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RPL3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RPL3
Name	ribosomal protein L3
Aliases	TARBP-B; HIV-1 TAR RNA-binding protein B; 60S ribosomal protein L3
Chromosomal Location	22q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RPL3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting RPL3.

ID	Name	Drug Type	Targets	#Targets
DB02494	Alpha-Hydroxy-Beta-Phenyl-Propionic Acid	Small Molecule	CPA1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, ......	14
DB04865	Omacetaxine mepesuccinate	Small Molecule	RPL3	1
DB07374	Anisomycin	Small Molecule	RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, ......	13
DB08437	Puromycin	Small Molecule	RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, ......	12
DB09092	Xanthinol	Small Molecule	GAPDH, IDH3A, MDH2, NNT, OGDH, RPL3	6

Browse RPL3